Clinical trials: Moderate to Severe Dry Eye
Eye Diseases
Efficacy of Different Treatment Regimens With Chitosan-N- Acetylcysteine in Moderate-to-severe Dry Eye Disease
Aim of this pilot study is to evaluate the best treatment regime of Chitosan-N-Acetylcysteine (Lacrimera®) compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
- Trial name
- NCT05053789
- Testing
- Lacrimera, Hylo-Vision
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Autoimmune Diseases, Dry Eye
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component.
- Conditions
- Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
- Trial name
- MNK (NCT06964269)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Phase 3 Study of EBI-005 in Dry Eye Disease
This is a phase III double-masked, randomized, controlled study evaluating the efficacy of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe DED three times…
- Trial name
- EBI-005 (NCT01998802)
- Testing
- Active Comparator EBI-005
- Where
- 45 sites in United States
- Volunteers
- 670 people
- Sponsor
- Eleven Biotherapeutics
Moderate to Severe Dry Eye Syndrome
Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
- Trial name
- NCT00814515
- Testing
- NOVA22007 (Ciclosporin 0.1%), NOVA22007
- Where
- France
- Volunteers
- 482 people
- Sponsor
- Santen SAS
Dry Eye Syndromes, Sjögren Syndrome
Comparison Between Rebamipide 2% Versus Autologous Serum
Two-period, controlled, randomized and open clinical trial. The sample was composed of adult women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who attended the ocular surface office, derived…
- Trial name
- NCT03608761
- Testing
- Rebamipide, autologous serum, autologous serum and rebamipide 2%
- Where
- Argentina
- Volunteers
- 21 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Dry Eye Syndromes
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT01568593
- Testing
- T2750, Vismed
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study of OT202 in Treating Moderate to Severe Dry Eye
This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.
- Trial name
- NCT06435182
- Testing
- OT202 conc 0.5%, OT202 conc 0.1%
- Where
- 10 sites in China
- Volunteers
- 213 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Dry Eye
Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score)…
- Trial name
- NCT06245421
- Testing
- DM934, Théalose
- Where
- 5 sites in France, Poland and 2 more
- Volunteers
- 85 people
- Sponsor
- Horus Pharma
Moderate to Severe Dry Eye Syndrome
Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease
This clinical trial is to investigate whether nonsteroid anti-inflammatory drops have therapeutic effect on moderate to severe dry eye patients.And compare the efficacy of the two nonsteroid anti-inflammatory drops with topical…
- Trial name
- NCT01562795
- Testing
- nonsteroid anti-inflammatory drops, corticosteroids, artificial tear substitute
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wenzhou Medical University
Dry Eye, Dry Eye Syndromes
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
In patients with moderate to severe dry eye syndrome, the test drug (HA 0.15% eye drop) or the control drug (cyclosporin 0.05% eye drop) is administered for 12 weeks, and the corneal staining of each group would be evaluated.
- Trial name
- NCT04127851
- Testing
- TJO-018 (HA 0.15%), Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add), TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
- Where
- South Korea
- Volunteers
- 438 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Dry Eye Disease
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
- Trial name
- NCT04084483
- Testing
- K-161
- Where
- 4 sites in United States
- Volunteers
- 238 people
- Sponsor
- Kowa Research Institute, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Dry Eye
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
- Trial name
- NCT04092907
- Testing
- HBM9036 0.25% Ophthalmic Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye Disease
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.
- Trial name
- NCT00679718
- Testing
- diquafosol tetrasodium (INS365) ophthalmic solution
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye
Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye
Comparison of two Dry Eye products
- Trial name
- NCT00724412
- Testing
- Systane, Optive
- Volunteers
- 279 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Study of TL-925 as a Treatment for Dry Eye Disease
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive…
- Trial name
- NCT05745064
- Testing
- TL-925
- Where
- 4 sites in United States
- Volunteers
- 107 people
- Sponsor
- Telios Pharma, Inc.
Dry Eye
Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18% in terms of cornea and…
- Trial name
- NCT03645850
- Testing
- Vismed gel Multi 0.3% eye drops, Vismed Multi 0.18% eye drops
- Volunteers
- 80 people
- Sponsor
- Horus Pharma
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea